1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 Instrument 1.2.3 Reagents and Consumables 1.2.4 Others 1.3 Market by Application 1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Tumor 1.3.3 Diabetes 1.3.4 Mental Diseases 1.3.5 Cardiovascular Diseases 1.3.6 Others 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2018-2029) 2.2 Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region 2.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2018-2023) 2.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029) 2.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics 2.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends 2.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers 2.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges 2.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue 3.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2018-2023) 3.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2018-2023) 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Pharmacogenomics Technology (Theranostics & CDx) Revenue 3.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio 3.4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2022 3.5 Pharmacogenomics Technology (Theranostics & CDx) Key Players Head office and Area Served 3.6 Key Players Pharmacogenomics Technology (Theranostics & CDx) Product Solution and Service 3.7 Date of Enter into Pharmacogenomics Technology (Theranostics & CDx) Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Type 4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2018-2023) 4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2024-2029) 5 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Application 5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2018-2023) 5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 6.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 7.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2018-2023) 8.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 9.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 9.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 10.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 Illumina 11.1.1 Illumina Company Detail 11.1.2 Illumina Business Overview 11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.1.5 Illumina Recent Development 11.2 Roche 11.2.1 Roche Company Detail 11.2.2 Roche Business Overview 11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.2.5 Roche Recent Development 11.3 Agilent 11.3.1 Agilent Company Detail 11.3.2 Agilent Business Overview 11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.3.5 Agilent Recent Development 11.4 Abbott 11.4.1 Abbott Company Detail 11.4.2 Abbott Business Overview 11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.4.5 Abbott Recent Development 11.5 Thermofisher 11.5.1 Thermofisher Company Detail 11.5.2 Thermofisher Business Overview 11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.5.5 Thermofisher Recent Development 11.6 Qiagen 11.6.1 Qiagen Company Detail 11.6.2 Qiagen Business Overview 11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.6.5 Qiagen Recent Development 11.7 Guardant Health 11.7.1 Guardant Health Company Detail 11.7.2 Guardant Health Business Overview 11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.7.5 Guardant Health Recent Development 11.8 MGI Tech Co., Ltd. 11.8.1 MGI Tech Co., Ltd. Company Detail 11.8.2 MGI Tech Co., Ltd. Business Overview 11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.8.5 MGI Tech Co., Ltd. Recent Development 11.9 Amoydx Biology 11.9.1 Amoydx Biology Company Detail 11.9.2 Amoydx Biology Business Overview 11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.9.5 Amoydx Biology Recent Development 11.10 Genomics 11.10.1 Genomics Company Detail 11.10.2 Genomics Business Overview 11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) 11.10.5 Genomics Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details